Perrigo Company plc executive Abigail Lennox, EVP and CSO, reported equity transactions on February 6, 2026. She exercised 3,185 Restricted Stock Units, converting them into the same number of ordinary shares at $14.64 per share. To cover tax obligations, 1,660 ordinary shares were withheld at $14.64. Following these transactions, she directly holds 2,780 ordinary shares and 6,368 Restricted Stock Units, each RSU representing a contingent right to receive one ordinary share, vesting in three equal annual installments beginning February 6, 2026.
Neuberger Berman Group LLC and Neuberger Berman Investment Advisers LLC report beneficial ownership of 7,535,309 Perrigo Co PLC common shares, representing 5.5% of the class. All voting and dispositive authority over these shares is shared, with no sole power reported. The firms state the holdings are managed in various fiduciary accounts where Perrigo shares are owned economically by underlying clients. They certify the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Perrigo.
BlackRock, Inc. filed an amended beneficial ownership report on Perrigo Company plc, stating that its reporting business units beneficially own 15,941,915 shares of Perrigo common stock, equal to 11.6 % of the class as of the reported date. BlackRock reports sole voting power over 15,479,279 shares and sole dispositive power over 15,941,915 shares, with no shared voting or dispositive power. The filing notes that one holder, iShares Core S&P Small-Cap ETF, has an interest in more than five percent of Perrigo’s outstanding common stock. BlackRock certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Perrigo.
Perrigo Company plc reported an insider equity award to one of its directors. On December 12, 2025, the director acquired 2,140 restricted stock units, each representing a contingent right to receive one ordinary share.
The restricted stock units are scheduled to vest on December 12, 2026. Following this grant, the director beneficially owns 41,160.148 ordinary shares on a direct basis.
Perrigo Company plc director Geoffrey Parker reported an equity award and his updated holdings in the company’s ordinary shares. On 12/12/2025, he received 2,140 Restricted Stock Units, each representing a contingent right to receive one Perrigo ordinary share, scheduled to vest on 12 December 2026.
After this award, he beneficially owns 28,912 ordinary shares directly, 25,879 ordinary shares through a revocable trust, 17,375 ordinary shares in a Roth IRA, and 2,140 Restricted Stock Units as a derivative security position.
Perrigo (PRGO): T. Rowe Price Associates, Inc. filed Amendment No. 3 to Schedule 13G reporting beneficial ownership of 16,920,302 shares of common stock, representing 12.3% of the class as of 09/30/2025.
The filer reports sole voting power over 16,856,660 shares and sole dispositive power over 16,920,302 shares, with no shared voting or dispositive power. T. Rowe Price files as an investment adviser and states the securities were acquired and are held in the ordinary course, not to change or influence control.
Within the reported holdings, T. Rowe Price Mid-Cap Value Fund has an interest in 9,190,014 shares, equal to 6.7% of the class.
Perrigo Co plc (PRGO) reported an insider transaction by director Geoffrey Parker. On 11/12/2025, Parker purchased 7,500 ordinary shares at a weighted average price of $14.18 per share, executed in multiple trades ranging from $14.16 to $14.20. The shares were acquired indirectly via a Roth IRA.
Following the transaction, Parker beneficially owned 17,375 shares indirectly (IRA), 28,912 shares directly, and 25,879 shares indirectly through a revocable trust where he and Jill Parker serve as trustees.
Perrigo Company plc reported third-quarter 2025 results. Net sales were $1,043.3 million versus $1,087.5 million a year ago, while operating income was $72.6 million versus $80.4 million. Net income was $7.5 million compared with a loss of $21.0 million in the prior-year quarter. Interest expense improved to $40.6 million from $57.6 million.
Year to date, sales were $3,143.5 million versus $3,235.1 million, with operating income of $164.9 million (versus a slight loss last year) and a net loss of $7.3 million (versus $127.3 million). Cash from operating activities was $63.1 million. Cash stood at $432.1 million and long‑term debt at $3,608.1 million. Inventories were $1,227.0 million.
The company agreed to sell its Dermacosmetics branded business for up to €327 million, including €300 million upfront and up to €27 million in earn‑outs, subject to regulatory and works council approvals, with closing expected in the first quarter of 2026. Related assets and liabilities held for sale were $280.5 million and $37.4 million, respectively. Shares outstanding were 137,624,009 as of October 31, 2025.
Perrigo Company plc (PRGO) furnished an 8-K announcing two items: it released earnings for the third quarter ended September 27, 2025 (Item 2.02), and it is initiating a strategic review of its infant formula business (Item 7.01). Both related press releases were furnished as Exhibits 99.1 and 99.2 on November 5, 2025.
The company highlighted use of non-GAAP measures to evaluate ongoing operating trends, comparability, and performance assessment. For recent periods, adjustments included amortization of acquired intangibles, unusual litigation, restructuring and termination benefits, impairment charges, infant formula remediation, divestiture gains or losses, foreign currency translation, non-GAAP tax adjustments, and other items. Management also references constant currency net sales and free cash flow among the metrics it reviews.
The earnings and strategic review press releases are expressly furnished, not filed, limiting their incorporation by reference under the Exchange Act and Securities Act.
Perrigo Company plc (PRGO) reporting person Matthew John Winterman received grants of restricted stock units on 07/08/2025 totaling 36,846 units: 31,319 RSUs and 5,527 RSUs. Each RSU represents a contingent right to receive one ordinary share. The filing shows no prior beneficial ownership before these reported transactions and records direct ownership of the 31,319 and 5,527 ordinary shares following the awards. The 31,319 RSUs include a vesting provision noted in the filing as vesting in two equal annual installments beginning July 8, 2026, while the 5,527 RSUs vest in three equal annual installments beginning July 8, 2026. The form is signed by an attorney-in-fact for Mr. Winterman and was filed on 08/22/2025.